Uncategorized
SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution
CAMBRIDGE, Mass.--(BUSINESS WIRE)--SciFluor Life Sciences, Inc., a clinical stage biopharmaceutical company that strives to create innovative best-in-class therapeutics for patients in multiple disease categories including ophthalmologic and neurologic disease, announced today that the first patients have been dosed in both Phase I/II trials of SF0166 Topical Ophthalmic Solution. This represents an important step forward in the clinical investigation of SF0166 Topical Ophthalmic Solution as a p
